<https://rdf.molmedb.upol.cz/reference/ref2600> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM472306>;
	<http://purl.org/ontology/bibo/pmid> "28947947"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acsmedchemlett.7b00293"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method30>,
		<https://rdf.molmedb.upol.cz/interaction/membrane18>;
	<http://purl.org/dc/terms/bibliographicCitation> "Hoegenauer K, Soldermann N, Zécri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J, Gutmann S, Rummel G, Littlewood-Evans A, Burkhart C.: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett, Volume 8 (9), 2017"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int981147> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref2600> .